The 31st National High School Manga Championship (Manga Koshien)
12.4.2022 09:00:00 EEST | Business Wire | Press release
What is Manga Koshien?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220408005170/en/
Flyer (Graphic: Business Wire)
It is a competition where teams of high school students compete on manga creations. This competition started in 1992 and celebrated its 30th anniversary last year. Since 2014, schools from overseas also started entering the competition, and we are seeing approximately 300 schools participating each year from Japan and abroad.
Teams of three to five students each work together to draw a one-page manga in accordance with a specified theme for the preliminaries. Those who manage to pass the preliminaries gather in Kochi during summer for the main round.
Teams in the main round (semifinals, revival round, finals) stand a chance to win the grand prize and other awards. This means prize money, drawing materials, and more! In addition, during the main round, talented students may even be scouted by major manga publishers and perhaps debut as professionals!
1. Preliminary Round Theme
- Space debris (Uchuu Gomi)
- ∞ Infinity (Mugen)
Draw and submit a one-page manga of either one of these themes.
Manga Koshien Website: https://mangaoukoku-tosa.jp/manga-koshien31/
2. Eligibility
- Japan and overseas senior high school students or similar (approximately 15 to 18 years of age)
- Only one team per school is allowed to participate.
3. Guidelines for the Preliminary Round Entries
- Entries should be submitted online at https://mangaoukoku-tosa.jp/manga-koshien31/
- The manga must be of B4 size (257mm x 364mm, in any orientation).
- The manga must be produced jointly by all students registered in the application form.
4. Timeline
(1) Preliminary Round (Online)
- Deadline: Tuesday, May 31st, 2022, 24:00 (JST)
- Judging: Tuesday, June 14th, 2022
- Chosen schools: 33 schools (30 from Japan, 3 from overseas)
(2) Main Round (Kochi Prefecture, Japan)
- Participants: 33 schools that passed the preliminary round
- Date: Saturday, 30th, and Sunday, 31st, July 2022
- Venue: Kochi Jibasan Center
- Participation fee: JPY 30,000 (per person)
*The participation fee will cover the participants’ air ticket, accommodation, etc.
*Travel arrangements will be made by the event organizer
5. Main Round Judges
- All 6 Preliminary Round Judges
-
Guest Judges
Fujimaki Tadatoshi (Famous works: Kuroko no Basuke, Robot x Laserbeam)
Yukimoto Shuuji (Famous works: Kemo Life, Shark Girl)
*For more details, please refer to the Implementation Outline at the following
URL: https://mangaoukoku-tosa.jp/manga-koshien31/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005170/en/
Contact information
In-charge: Yasuaki Okamatsu, Risa Matsumoto
Manga Kingdom Tosa Promotional Committee
(within the Manga Kingdom Tosa Office)
TEL: +81-(0)88-823-9711 FAX: +81-(0)88-823-9296
Email: 140201@ken.pref.kochi.lg.jp
Website: https://mangaoukoku-tosa.jp/manga-koshien31/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom